U.S. Cannabis Pharmaceuticals Market Size & Outlook
U.S. cannabis pharmaceuticals market, 2018-2030 (US$M)
Related Markets
U.S. cannabis pharmaceuticals market highlights
- The U.S. cannabis pharmaceuticals market generated a revenue of USD 585.0 million in 2023 and is expected to reach USD 19,727.4 million by 2030.
- The U.S. market is expected to grow at a CAGR of 65.3% from 2024 to 2030.
- In terms of segment, epidiolex was the largest revenue generating brand type in 2023.
- Other Brands is the most lucrative brand type segment registering the fastest growth during the forecast period.
Cannabis pharmaceuticals market data book summary
| Market revenue in 2023 | USD 585.0 million |
| Market revenue in 2030 | USD 19,727.4 million |
| Growth rate | 65.3% (CAGR from 2023 to 2030) |
| Largest segment | Epidiolex |
| Fastest growing segment | Other Brands |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Epidiolex, Other Brands |
| Key market players worldwide | Jazz Pharmaceuticals PLC, AbbVie Inc, Insys Therapeutics, Bausch Health Companies Inc |
Other key industry trends
- In terms of revenue, U.S. accounted for 17.1% of the global cannabis pharmaceuticals market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In North America, U.S. cannabis pharmaceuticals market is projected to lead the regional market in terms of revenue in 2030.
- Canada is the fastest growing regional market in North America and is projected to reach USD 11,585.2 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Cannabis Pharmaceuticals Market Scope
Cannabis Pharmaceuticals Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
U.S. cannabis pharmaceuticals market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to cannabis pharmaceuticals market will help companies and investors design strategic landscapes.
Epidiolex was the largest segment with a revenue share of 66.68% in 2023. Horizon Databook has segmented the U.S. cannabis pharmaceuticals market based on epidiolex, other brands covering the revenue growth of each sub-segment from 2018 to 2030.
The U.S. accounted for the highest share of the market in North America in 2023. This can be attributed to the high utilization of medical cannabis owing to government approvals. For instance, the FDA approved Epidiolex for use in 2018. This sanction paved the way for the adoption of cannabis for the treatment of medical conditions, such as seizures and chronic pain.
As of 2023, the use of medical marijuana is legal in around 38 states and the District of Columbia. These states have proper, publicly available medical marijuana plans or programs.
Reasons to subscribe to U.S. cannabis pharmaceuticals market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of U.S. cannabis pharmaceuticals market databook
-
Our clientele includes a mix of cannabis pharmaceuticals market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. cannabis pharmaceuticals market , including forecasts for subscribers. This country databook contains high-level insights into U.S. cannabis pharmaceuticals market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
U.S. cannabis pharmaceuticals market size, by brand type, 2018-2030 (US$M)
U.S. Cannabis Pharmaceuticals Market Outlook Share, 2023 & 2030 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
